Third Harmonic Bio, Inc. THRD
Institutional shares held
43.6 Million
7.1K
calls
0
puts
Total value of holdings
$572M
$93K
calls
$0
puts
Market Cap
$515M
40,328,900
Shares Out.
Institutional ownership
108.19%
# of Institutions
83
We take great care to ensure that the data presented and summarized in this overview for Third Harmonic Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding THRD
View all-
Atlas Venture Life Science Advisors, LLC10.9MShares$139 Million18.24% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.78MShares$73.7 Million1.85% of portfolio
-
Bvf Inc San Francisco, CA4.37MShares$55.7 Million1.88% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.18MShares$40.6 Million1.87% of portfolio
-
General Atlantic LLC New York, NY2.96MShares$37.8 Million1.15% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.83MShares$36.1 Million0.02% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.42MShares$30.8 Million4.25% of portfolio
-
Boxer Capital, LLC San Diego, CA2MShares$25.5 Million1.44% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$18.2 Million0.0% of portfolio
-
Commodore Capital LP New York, NY1.36MShares$17.4 Million1.57% of portfolio
Latest Institutional Activity in THRD
Top Purchases
Top Sells
About THRD
Insider Transactions at THRD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2024
|
Edward R. Conner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,117
-100.0%
|
$31,755
$15.0 P/Share
|
|
Nov 08
2024
|
Edward R. Conner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,117
+50.0%
|
$8,468
$4.2 P/Share
|
|
Nov 01
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Other acquisition or disposition
|
Direct |
515,688
-5.0%
|
-
|
|
Oct 29
2024
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
1,000,000
-24.12%
|
$14,000,000
$14.3 P/Share
|
|
Oct 28
2024
|
Edward R. Conner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,673
-100.0%
|
$40,095
$15.0 P/Share
|
|
Oct 28
2024
|
Edward R. Conner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,673
+50.0%
|
$10,692
$4.2 P/Share
|
|
Sep 19
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,497
-100.0%
|
$132,958
$14.29 P/Share
|
|
Sep 19
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Exercise of conversion of derivative security
|
Direct |
9,497
-50.0%
|
$37,988
$4.2 P/Share
|
|
Sep 19
2024
|
Edward R. Conner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,790
-100.0%
|
$71,850
$15.0 P/Share
|
|
Sep 19
2024
|
Edward R. Conner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,790
+50.0%
|
$19,160
$4.2 P/Share
|
|
Sep 18
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
503
-100.0%
|
$7,042
$14.0 P/Share
|
|
Sep 18
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
503
+50.0%
|
$2,012
$4.2 P/Share
|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$120,000
$12.46 P/Share
|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.2 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
494
-100.0%
|
$6,916
$14.17 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
494
-50.0%
|
$1,976
$4.2 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
1,042
-100.0%
|
$14,588
$14.0 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
1,042
-50.0%
|
$4,168
$4.3 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
23,578
-100.0%
|
$330,092
$14.04 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,578
+36.33%
|
$94,312
$4.25 P/Share
|
Last 12 Months Summary
Buy / Acquisition
96.2K
Shares
From
4
Insiders
| Exercise of conversion of derivative security | 72.6K shares |
|---|---|
| Grant, award, or other acquisition | 23.6K shares |
Sell / Disposition
1.63M
Shares
From
8
Insiders
| Open market or private sale | 1.11M shares |
|---|---|
| Other acquisition or disposition | 516K shares |
| Exercise of conversion of derivative security | 9.5K shares |
| Grant, award, or other acquisition | 1.54K shares |